



Esteve RD UK & Ireland Ltd
The Round House
The Courtyard Barns
Choke Lane, Cookham Dean
Maidenhead, Berkshire,
SL6 6PT
www.esteve.com
VAT Number: GB 948 5288 70

Dear Sir or Madam

On July 10th, 2024, ESTEVE, a global pharmaceutical company headquartered in Barcelona, Spain, successfully completed the acquisition of HRA Pharma Rare Diseases, including HRA Pharma UK & Ireland Limited from Perrigo Company plc. This strategic move marks a milestone that heralds an exciting new chapter for our organization, as we join forces to enhance our capabilities in addressing rare and severe diseases.

This acquisition brings together two experts in the healthcare industry, unified by a shared commitment to addressing unmet medical needs. With our combined assets, we are well-positioned to accelerate our mission of providing solutions to patients around the world.

Esteve RD UK & Ireland is based in Maidenhead and employs a small number of specialist staff looking after all pharmacovigilance, quality, sales, and marketing activities for HRA Pharma UK & Ireland Limited and latterly Esteve RD UK & Ireland products distributed in these territories. The UK Company has agreed to comply with the ABPI Code of Practice for the Pharmaceutical Industry and accepts the jurisdiction of the Prescriptions Medicines Code of Practice Authority (PMCPA). This disclosure reflects all transfers of value (ToV), subject to the ABPI code of practice, completed during 2024 and involving United Kingdom Health Care Professionals (HCPs) and Healthcare Organisations (HCOs).

These transfers of value include:

- Collaborative Working (which includes joint working).
- Donations, grants and benefits provided to institutions, organisations and associations.
- Sponsorship of attendance by health professionals and other relevant decision makers at meetings.
- Fees and expenses paid to Health Care Professionals and other relevant decision makers, or to their employers on their behalf.
- Contributions towards the costs of meetings paid to Health Care Professionals or to third parties managing events on their behalf, which may include sponsorship of health professionals by way of registration fees and accommodation and travel.

Please note that the ToVs between Jan 2024 – and Mid-July were under the ownership of Perrigo and then subsequently, following the acquisition by ESTEVE, under the ownership of Esteve RD UK & Ireland.

We have made the company decision to disclose the full year 2024 under HRA Pharma UK & Ireland Limited.

To ensure compliance with this undertaking all Health Care Professionals engaged by Esteve RD UK & Ireland are required to sign a contract which includes a clause on transparency, which explicitly sets out the requirements for disclosure. As can be appreciated from the disclosure, Esteve RD UK & Ireland engages with Health Care Professionals in a very limited fashion and such engagement is most often specific to identified business needs requiring expert clinical advice or an expert clinical speaker.

Regarding the mechanics of payment, transfers of value are made in pounds sterling to the individual, business or organisation as appropriate:

- ToV are reported in Great British Pounds (GBP).
- VAT is only paid where the recipient is VAT registered and has provided a bona fide VAT invoice.
- Any tax liability resulting from a transfer of value is the sole responsibility of the recipient.
- Where currency conversion is required the exchange rate applied is that of the date of transfer.
- Amounts stated are the total value received for the calendar year in question.



Esteve RD UK & Ireland Ltd
The Round House
The Courtyard Barns
Choke Lane, Cookham Dean
Maidenhead, Berkshire,
SL6 6PT
www.esteve.com
VAT Number: GB 948 5288 70

Esteve RD UK & Ireland is committed to preserving the integrity and transparency in our interactions with HCPs, ORDMs and HCOs, therefore, we are now pleased to share with you our disaggregated 2024 disclosures.

For all enquiries regarding this declaration please contact: Tel. 01628 771 800

Yours sincerely,

Signed by:

6DB4394BE18A440...

Scott Hall
Managing Director